Você procurou por: control subjects (Inglês - Maltês)

hiv-negative matched control subjects
individwi bil-kontroll imqabbel negattivi għall-hiv

exemption subject to end-use control
l-eżenzjoni subordinata għall-kontroll ta' l-użu partikolari

include stocks which are subject to government control.
jinkludu l-istokks li huma soġġetti għal kontroll governattiv.

in subjects with creatinine clearance between 30 and 50 ml/min, auctf was twofold greater compared with control subjects.
f’individwi bi tneħħija tal-kreatinina bejn 30 u 50 ml/min, l-auctf kienet darbtejn aktar meta mqabbla mal-individwi bħala kontroll.

patients with mild renal insufficiency did not have a clinically meaningful increase in the plasma concentration of sitagliptin as compared to normal healthy control subjects.
il- pazjenti b’ insuffiċjenza renali ħafifa ma kellhomx żieda klinikament sinifikanti fil- konċentrazzjoni fil- plażma ta ’ sitagliptin meta mqabbla ma ’ suġġetti normali f’ saħħithom bħala kontroll.

the pharmacokinetics of abiraterone acetate was compared in patients with end-stage renal disease on a stable haemodialysis schedule versus matched control subjects with normal renal function.
il-farmakokinetika ta’ abiraterone acetate tqabblet f’pazjenti b’mard tal-kliewi tal-aħħar stadju fuq skeda stabbli ta’ dijalisi versus individwi mqabbla ta’ kontroll b’funzjoni normali tal-kliewi.

total exposure to alogliptin was approximately 10% lower and peak exposure was approximately 8% lower in patients with moderate hepatic impairment compared to healthy control subjects.
l-espożizzjoni totali għal alogliptin kienet ta’ madwar 10% aktar baxxi u l-espożizzjoni massima kienet madwar 8% iktar baxxa f’pazjenti b’indeboliment tal-fwied moderat meta mqabbel ma’ individwi b’saħħithom bħala kontroll.

elimination half-life was significantly longer in class c and class a patients than in control subjects (mean t1/ 2 of 59 and 32 versus 22 minutes).
wara doża singola orali ta ’ 25mg/ kg, il- valuri ta ’ auc kienu d- doppju f’ pażjenti b’ ċirrożi, b’ clearance orali evidenti li naqas minn 9. 1 minn f’ adulti f’ saħħithom sa 4. 5 u 4. 1 ml/ min/ kg f’ pazjenti b ’ class a (mingħajr axxite) u b ’ class c (b’ axxite) milli f’ pazjenti fil- kontrol (medja t1/ 2 ta ’ ta ’ 59 u 32 versus 22 minuti).

laropiprant: administration of laropiprant 40 mg in non-dialysed patients with severe renal insufficiency resulted in no clinically meaningful change in the auc and cmax of laropiprant, compared to healthy control subjects.
laropiprant: l-għoti ta’ laropiprant 40 mg f’pazjenti mhux fuq dijalisi b’insuffiċjenza renali severa ma rriżulta f’ebda bidla klinikament sinifikanti fl-auc u l-cmax ta’ laropiprant, meta mqabbel ma’ individwi ta’ kontroll b’saħħithom.

in patients with mild hepatic impairment (child-pugh a), the mean auc and cmax increased 17% and 22% respectively, compared to healthy control subjects.
f’pazjenti li kellhom indeboliment tal-fwied ħafif (child-pugh a), l-auc medja għoliet b’17% u s-cmax għoliet b’ 22% meta mqabbla ma’ grupp ta’ kontroll ta’ rġiel b’saħħithom.

at 5 years after primary vaccination, there were significantly higher percentages of subjects with hsba ≥ 1:8 in the menveo group than in the vaccine-naive control subjects against all the four serogroups.
5 snin wara t-tilqima primarja, kien hemm perċentwali ogħla b’mod sinifikanti ta’ individwi b’hsba ta’ ≥ 1:8 fil-grupp ta’ menveo milli f’individwi tal-kontroll li qatt ma ngħataw tilqima kontra l-erba’ serogruppi kollha.

however, as the distribution of auc values for alogliptin in these patients was within the same range as control subjects, no dose adjustment of alogliptin for patients with mild renal impairment is necessary (see section 4.2).
madankollu, peress li d-distribuzzjoni ta’ valuri ta’ auc għal alogliptin f’dawn il-pazjenti kienet fl-istess firxa bħall-individwi tal-kontroll, l-ebda aġġustament fid-doża ta’ alogliptin għal pazjenti b’indeboliment ħafif tal-kliewi ma hija neċessarja (ara sezzjoni 4.2).

the plasma amprenavir pharmacokinetics were evaluated in a 14 day repeat-dose study in hiv-1 infected adult subjects with mild, moderate, or severe hepatic impairment receiving fosamprenavir with ritonavir compared to matched control subjects with normal hepatic function.
il- farmakokinetiċi ta ’ amprenavir fil- plażma ġew evalwati fi studju ta ’ 14- il ġurnata b’ doża ripetuta f’ suġġetti adulti bl- infezzjoni hiv- 1 u b’ indeboliment tal- fwied ħafif, moderat jew sever li qegħdin jirċievu fosamprenavir flimkien ma ’ ritonavir u dawn ġew mqabbla ma 'suġġetti simili b’ funzjoni tal - fwied normali bħala kontroll.

a single-dose, open-label study was conducted to evaluate the pharmacokinetics of a reduced dose of sitagliptin (50 mg) in patients with varying degrees of chronic renal impairment compared to normal healthy control subjects.
sar studju bil-mediċina magħrufa u b’doża waħda biex jevalwa l-effetti farmakokinetiċi ta’ doża mnaqqsa ta’sitagliptin (50 mg) f’pazjenti b’indeboliment renali kroniku fi stadji differenti, meta mqabbel mal-individwi ta’ kontroll b’saħħithom normali.

renal insufficiency a single-dose, open-label study was conducted to evaluate the pharmacokinetics of a reduced dose of sitagliptin (50 mg) in patients with varying degrees of chronic renal insufficiency compared to normal healthy control subjects.
indeboliment tal- kliewi sar studju b’ doża waħda, b’ tikketta miftuħa biex jevalwa l- farmakokinetika ta ’ doża mnaqqsa ta ’ sitagliptin (50 mg) f’ pazjenti bi gradi li jvarjaw ta ’ indeboliment tal- kliewi kroniku meta mqabbla ma ’ suġġetti ta ’ kontroll normali b’ saħħithom.

renal insufficiency a single-dose, open-label study was conducted to evaluate the pharmacokinetics of a reduced dose of sitagliptin (50-mg) in patients with varying degrees of chronic renal insufficiency compared to normal healthy control subjects.
sar studju open- label u b’ do a wa da biex jevalwa l- farmakokinetika ta ’ do a mnaqqsa ta ’ sitagliptin (50 mg) f’ pazjenti b’ insuffi jenza renali kronika fi stadji differenti, kkomparati ma ’ individwi f’ sa ithom b ala kontroll.

absorption of deuterated tocofersolan showed a normal pattern in lipoproteins: alpha- tocopherol peaked first in chylomicrons, then in very low- density lipoproteins (vldl) and finally in low- density lipoproteins (ldl) and high-density lipoproteins (hdl), and the disappearance portions of the curves paralleled those in control subjects.
l-assorbiment ta’ tocofersolan dewterat wera skema normali f’lipoproeini: alpha-tocopherol kien l-aktar għoli l-ewwel f’chylomicrons, imbagħad f’lipoproteini ta’ densità baxxa ħafna (vldl) u finalment fi proteini ta’ densità baxxa (ldl) u lipoproteini ta’ densità għolja (hdl), u l-porzjonijiet li jisparixxu tal- kurvi kienu paralleli għal dawk f’individwi li ntużaw bħala kontroll.